Osaka – Drugmaker Shionogi & Co. aims to establish adequate annual production capacity for its planned novel coronavirus vaccine for 30 million people by the end of 2021, informed sources said Monday.
The amount triples the firm’s initial target. The company will raise its output for stable domestic supply to prepare for a resurgence of COVID-19 cases, the sources said.
Shionogi plans to start a clinical trial as early as November this year, hoping to launch the vaccine in autumn next year.
It is developing the vaccine using insect cells with technology held by subsidiary UMN Pharma Inc. The vaccine will be mass-produced at a facility of Unigen Inc., a contract drug manufacturer.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.